DCT

1:26-cv-01073

Bayer Healthcare Pharma Inc v. Saba Ilac Sanayi Ve Ticaret A S

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: Bayer HealthCare Pharmaceuticals Inc. v. Saba Ilac Sanayi ve Ticaret A. S., 1:26-cv-01073, D. Del., 08/21/2026
  • Venue Allegations: Venue is alleged to be proper because Defendant is a foreign corporation, and the complaint asserts that Defendant is subject to personal jurisdiction in Delaware. The complaint further alleges that Defendant has purposely availed itself of doing business in Delaware, maintains systematic contacts, and has previously consented to jurisdiction in the district in other litigation.
  • Core Dispute: This is a patent infringement action under the Hatch-Waxman Act, where Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's drug KERENDIA® (finerenone) constitutes an act of infringement of a patent covering the drug's active ingredient.
  • Technical Context: The technology concerns a non-steroidal small molecule compound, finerenone, which functions as a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease and certain cardiovascular conditions.
  • Key Procedural History: The action was triggered by Defendant's submission of ANDA No. 220708 with a Paragraph IV certification, asserting that U.S. Patent No. 8,436,180 is invalid, unenforceable, or will not be infringed by its proposed generic product. Plaintiff initiated this lawsuit within the 45-day statutory window following receipt of Defendant's notice letter. The complaint notes separate, pending litigation between the parties in the same district concerning a different patent also related to KERENDIA®.

Case Timeline

Date Event
2007-02-27 '180 Patent Priority Date
2013-05-07 '180 Patent Issue Date
2021-07-09 FDA Approval of KERENDIA® (NDA No. 215341)
2026-07-07 Defendant Sends Paragraph IV Notice Letter
2026-07-09 New Chemical Entity Exclusivity for KERENDIA® Expires
2026-08-21 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,436,180 - "Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof"

  • Issued: May 7, 2013.

The Invention Explained

  • Problem Addressed: The patent's background section describes how the hormone aldosterone, while crucial for regulating fluid and electrolyte balance, can be detrimental when present in excessive concentrations (hyperaldosteronism) ʼ180 Patent, col. 1:47-53 This condition can contribute to hypertension, heart failure, and adverse cardiac remodeling ʼ180 Patent, col. 2:5-12 The patent notes that existing aldosterone antagonists are steroidal compounds that can cause significant side effects, such as gynecomastia and impotence, by interacting with other steroid hormone receptors ʼ180 Patent, col. 2:56-62
  • The Patented Solution: The ʼ180 Patent discloses a new class of non-steroidal mineralocorticoid receptor antagonists, specifically substituted 4-aryl-1,4-dihydro-1,6-naphthyridine-3-carboxamides ʼ180 Patent, abstract These compounds, represented by the general chemical structure in Formula (I), are designed to be more selective for the mineralocorticoid receptor, thereby offering a "distinct therapeutic advantage" by avoiding the side effects associated with prior steroidal drugs ʼ180 Patent, col. 2:65-67 ʼ180 Patent, col. 3:25-32
  • Technical Importance: The development of a selective, non-steroidal mineralocorticoid receptor antagonist provided a new therapeutic pathway for treating cardiovascular and related disorders without the hormone-related side effect profile of older, steroidal drugs ʼ180 Patent, col. 2:62-67

Key Claims at a Glance

  • The complaint alleges infringement of "one or more claims" without specifying particular claims Compl. ¶38 The infringement theory is based on the allegation that the accused product contains the compound finerenone Compl. ¶38 Independent Claim 1 is a genus claim covering a class of compounds.
  • Independent Claim 1: A compound of the formula (I), or a salt thereof, with specified substituent groups, including:
    • A core 1,4-dihydro-1,6-naphthyridine structure.
    • An aryl group ("Ar") at the 4-position.
    • An alkyl group ("R¹") at the 2-position.
    • A carboxamide group ("CONH2") at the 3-position.
    • Various specified substitutions ("D", "R²", "R³") on the naphthyridine ring system.
  • The complaint does not explicitly reserve the right to assert dependent claims, but its general allegation of infringing "one or more claims" leaves this possibility open. Notably, Claim 5 of the patent claims specific enantiomeric compounds, including the structure corresponding to finerenone.

III. The Accused Instrumentality

Product Identification

The accused instrumentality is Defendant SABA's proposed generic finerenone tablet in 10 mg and 20 mg dosages, for which it seeks FDA approval under ANDA No. 220708 Compl. ¶1 Compl. ¶28

Functionality and Market Context

  • The product is a generic equivalent of Bayer's brand-name drug, KERENDIA® Compl. ¶1
  • The active pharmaceutical ingredient is finerenone, a non-steroidal mineralocorticoid receptor antagonist (nsMRA) Compl. ¶20
  • The proposed product is indicated for reducing the risk of kidney function decline, kidney failure, cardiovascular death, heart attacks, and hospitalization for heart failure in certain patient populations with chronic kidney disease and/or heart failure Compl. ¶20
  • The complaint alleges that SABA intends to commercially manufacture and sell its ANDA Product in the United States before the expiration of the ʼ180 Patent Compl. ¶26

IV. Analysis of Infringement Allegations

The complaint asserts infringement under 35 U.S.C. § 271(e)(2)(A), which defines the submission of an ANDA for a drug claimed in a patent as a statutory act of infringement Compl. ¶36 The substantive infringement allegation is that the Defendant's proposed product contains finerenone, a compound allegedly covered by the claims of the '180 Patent Compl. ¶38 No probative visual evidence provided in complaint.

'180 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A compound of the formula (I) ... or a salt thereof. The complaint alleges that SABA's ANDA Product contains the active pharmaceutical ingredient finerenone, which is a compound that falls within the scope of the general structure of formula (I). ¶38 col. 3:25-32

Identified Points of Contention

  • Scope Questions: In this type of pharmaceutical litigation, where the generic product is intended to be a bioequivalent copy of the branded drug, literal infringement of a compound claim is often not the central dispute. The primary question is typically patent validity. The complaint itself seeks a declaratory judgment of both infringement and "no invalidity," signaling an expected validity challenge Compl. ¶1
  • Technical Questions (related to Validity): The complaint notes that SABA's Paragraph IV notice letter alleges the ʼ180 Patent is invalid as anticipated and/or obvious over U.S. Patent No. 8,404,709 Compl. ¶30 Compl. ¶56 This raises a key question for the case: does the disclosure of the '709 patent render the claims of the ʼ180 Patent invalid? Further, SABA has alleged invalidity under 35 U.S.C. § 112 for lack of written description, enablement, and indefiniteness Compl. ¶30, which will require the court to evaluate the adequacy of the ʼ180 Patent's disclosure relative to its claims.

V. Key Claim Terms for Construction

The complaint does not provide sufficient detail to identify specific claim terms that are likely to be central to a construction dispute. In pharmaceutical compound litigation of this nature, where infringement is alleged because the accused product contains the patented chemical entity, disputes often center on patent validity rather than the construction of standard chemical terms. The defendant's challenges, as described in the complaint, focus on validity under sections 102, 103, and 112, rather than on the meaning of any particular term in the claims Compl. ¶30

VI. Other Allegations

Indirect Infringement

The complaint alleges that upon FDA approval, SABA will induce and contribute to infringement by third parties Compl. ¶49 The basis for this allegation is that SABA knows and intends for healthcare professionals and patients to use its generic product according to the instructions on the product's label, which would constitute an infringing use of the patented compound Compl. ¶49

Willful Infringement

Willfulness is alleged based on SABA's "full knowledge of the '180 Patent" and the alleged lack of a "reasonable basis for believing" its product would not infringe or that the patent is invalid Compl. ¶41 This allegation is predicated on SABA's Paragraph IV certification and its associated notice letter, which demonstrate pre-suit knowledge of the patent Compl. ¶27 Compl. ¶41

VII. Analyst's Conclusion: Key Questions for the Case

This case presents a classic Hatch-Waxman dispute where the central battleground will almost certainly be patent validity rather than infringement. The key questions for the court appear to be:

  • A primary issue will be one of validity over prior art: Are the claims of the ʼ180 Patent, which cover the finerenone compound, invalid as anticipated or obvious in light of the cited prior art, U.S. Patent No. 8,404,709, as alleged in SABA's notice letter?
  • A second critical issue will be one of compliance with 35 U.S.C. § 112: Does the ʼ180 Patent's specification provide adequate written description and enablement to support the full scope of the asserted claims, and are those claims sufficiently definite to inform one of ordinary skill in the art of their boundaries?
  • A final question, likely secondary to validity, concerns willfulness: Did SABA lack an objectively reasonable, good-faith belief in its non-infringement or invalidity positions when it filed its ANDA, thereby exposing it to potential enhanced damages if its validity challenges fail?